-
公开(公告)号:US09920047B2
公开(公告)日:2018-03-20
申请号:US15270863
申请日:2016-09-20
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Shigemitsu Matsumoto , Yasushi Hattori , Masashi Toyofuku , Shinji Morimoto , Masaki Daini , Takuto Kojima , Tomohiro Kaku , Mitsuhiro Ito
IPC: C07D417/14 , C07D417/12 , C07D409/12 , C07D307/79 , C07D407/12 , C07D213/82 , C07D333/38 , C07D413/14 , C07D231/14 , C07D333/40 , C07D285/135 , C07D231/12 , C07D277/56 , C07D409/14 , C07D413/12 , C07D307/81 , C07D285/08
CPC classification number: C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号:US09499568B2
公开(公告)日:2016-11-22
申请号:US14804935
申请日:2015-07-21
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masakuni Kori , Toshihiro Imaeda , Shinji Nakamura , Masashi Toyofuku , Eiji Honda , Osamu Ujikawa
IPC: C07D513/04
CPC classification number: C07D513/04
Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
-
公开(公告)号:US09493484B2
公开(公告)日:2016-11-15
申请号:US14377106
申请日:2013-02-07
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masashi Toyofuku , Shinji Nakamura , Eiji Honda
IPC: C07D513/04 , C07D513/08 , C07D513/18
CPC classification number: C07D513/08 , C07D513/04 , C07D513/18
Abstract: Provided is a compound having an AMPA receptor function enhancing action, and useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD) and the like. The compound represented by formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof has an AMPA receptor function enhancing action, and is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
-
公开(公告)号:US10968213B2
公开(公告)日:2021-04-06
申请号:US16455359
申请日:2019-06-27
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Shigemitsu Matsumoto , Yasushi Hattori , Masashi Toyofuku , Shinji Morimoto , Masaki Daini , Takuto Kojima , Tomohiro Kaku , Mitsuhiro Ito
IPC: C07D417/14 , C07D417/12 , C07D409/12 , C07D307/79 , C07D407/12 , C07D213/82 , C07D333/38 , C07D413/14 , C07D231/14 , C07D333/40 , C07D285/08 , C07D285/135 , C07D231/12 , C07D277/56 , C07D409/14 , C07D413/12 , C07D307/81 , A61P43/00 , A61P35/00 , A61P25/28 , A61P25/18 , A61P25/16 , A61P25/14 , A61P25/08 , A61P25/00 , A61K31/343 , A61K31/421 , A61K31/433
Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号:US10414761B2
公开(公告)日:2019-09-17
申请号:US15882386
申请日:2018-01-29
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Shigemitsu Matsumoto , Yasushi Hattori , Masashi Toyofuku , Shinji Morimoto , Masaki Daini , Takuto Kojima , Tomohiro Kaku , Mitsuhiro Ito
IPC: C07D417/14 , C07D417/12 , C07D409/12 , C07D307/79 , C07D407/12 , C07D213/82 , C07D333/38 , C07D413/14 , C07D231/14 , C07D333/40 , C07D285/08 , C07D231/12 , C07D277/56 , C07D409/14 , C07D413/12 , C07D307/81 , C07D285/135
Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号:US10053456B2
公开(公告)日:2018-08-21
申请号:US15302405
申请日:2015-04-09
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Shigemitsu Matsumoto , Yasushi Hattori , Masashi Toyofuku , Shinji Morimoto , Masaki Daini , Takuto Kojima , Tomohiro Kaku , Mitsuhiro Ito
IPC: C07D417/14 , C07D307/81 , C07D231/12 , C07D277/56 , C07D409/14 , C07D413/12 , C07D413/14 , C07D285/135 , C07D285/08 , C07D333/40 , C07D231/14 , C07D333/38 , C07D407/12 , C07D307/79 , C07D409/12 , C07D417/12 , C07D213/82
CPC classification number: C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号:US09714241B2
公开(公告)日:2017-07-25
申请号:US15203551
申请日:2016-07-06
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Shigemitsu Matsumoto , Yasushi Hattori , Masashi Toyofuku , Shinji Morimoto , Takuto Kojima , Tomohiro Kaku , Mitsuhiro Ito
IPC: C07D417/12 , C07D417/14 , C07D213/82 , C07D333/38 , C07D285/135 , C07D409/14 , C07D231/12 , C07D413/14 , C07D277/56 , C07D409/12 , C07D307/79 , C07D407/12 , C07D231/14 , C07D333/40 , C07D285/08 , C07D413/12 , C07D307/81
CPC classification number: C07D417/14 , C07D213/82 , C07D231/12 , C07D231/14 , C07D277/56 , C07D285/08 , C07D285/135 , C07D307/79 , C07D307/81 , C07D333/38 , C07D333/40 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12
Abstract: The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
-
公开(公告)号:US09884875B2
公开(公告)日:2018-02-06
申请号:US15289650
申请日:2016-10-10
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masakuni Kori , Toshihiro Imaeda , Shinji Nakamura , Masashi Toyofuku , Eiji Honda
IPC: C07D513/04
CPC classification number: C07D513/04
Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
-
公开(公告)号:US20150266881A1
公开(公告)日:2015-09-24
申请号:US14435085
申请日:2013-10-11
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor: Naoki Tomita , Daisuke Tomita , Yusuke Tominari , Shinichi Imamura , Shinji Morimoto , Takuto Kojima , Masashi Toyofuku , Yasushi Hattori , Tomohiro Kaku , Mitsuhiro Ito
IPC: C07D487/04 , C07D231/38 , C07C237/38 , C07C237/30 , C07D241/12 , C07D213/36 , C07D471/04 , C07D207/46 , C07D241/18 , C07D319/18 , C07D265/36 , C07D333/20 , C07D285/135 , C07D277/38 , C07D405/12 , C07D417/12 , C07D413/12 , C07D223/12 , C07D513/04 , C07C237/40
CPC classification number: C07D487/04 , A61K45/06 , C07C237/30 , C07C237/38 , C07C237/40 , C07C255/29 , C07C255/58 , C07C255/60 , C07C317/40 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/12 , C07D207/46 , C07D211/58 , C07D213/36 , C07D213/40 , C07D223/12 , C07D231/38 , C07D231/40 , C07D241/12 , C07D241/18 , C07D261/14 , C07D265/36 , C07D277/38 , C07D285/135 , C07D295/135 , C07D309/14 , C07D319/18 , C07D333/20 , C07D405/12 , C07D413/12 , C07D417/12 , C07D471/04 , C07D513/04
Abstract: The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); B is a benzene ring optionally having further substituent(s); R1, R2 and R3 are each independently a hydrogen atom, a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s); A and R1 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s); and R2 and R3 are optionally bonded to each other to form, together with the adjacent nitrogen atom, a cyclic group optionally having substituent(s), or a salt thereof.
Abstract translation: 本发明提供了具有赖氨酸特异性脱甲基酶1抑制作用的化合物,可用作精神分裂症,阿尔茨海默病,帕金森病或亨廷顿病等预防或治疗药物等药物。 本发明涉及由下式表示的化合物:其中A是任选具有取代基的烃基或任选具有取代基的杂环基; B是任选具有其它取代基的苯环; R 1,R 2和R 3各自独立地为氢原子,任选具有取代基的烃基或任选具有取代基的杂环基; A和R1任选地彼此键合,与相邻的氮原子一起形成任选具有取代基的环状基团; R 2和R 3可以相互键合,与相邻的氮原子一起形成任选具有取代基的环状基团或其盐。
-
公开(公告)号:US08916551B2
公开(公告)日:2014-12-23
申请号:US13774707
申请日:2013-02-22
Applicant: Takeda Pharmaceutical Company Limited
Inventor: Masakuni Kori , Toshihiro Imaeda , Shinji Nakamura , Masashi Toyofuku , Eiji Honda
IPC: C07D513/04
CPC classification number: C07D513/04
Abstract: Provided is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof, which has an AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor potentiating action. The compound of the present invention is useful as a prophylactic or therapeutic drug for depression, schizophrenia, Alzheimer's disease or attention deficit hyperactivity disorder (ADHD) and the like.
Abstract translation: 提供由式(I)表示的化合物:其中每个符号如说明书中所定义,或其盐,其具有AMPA(α-氨基-3-羟基-5-甲基-4-异恶唑丙酸)受体 增效作用 本发明的化合物可用作抑郁症,精神分裂症,阿尔茨海默病或注意缺陷多动障碍(ADHD)等的预防或治疗药物。
-
-
-
-
-
-
-
-
-